About InterpretOmics
InterpretOmics is a company based in Bengaluru (India) founded in 2009 by Amrith Prasad and Archana Prahlad. InterpretOmics has raised $1.92 million across 2 funding rounds from investors including Amarante Shipping, Somaprasad Muttael Prabhakaran and Prashant Priya. The company has 56 employees as of April 05, 2024. InterpretOmics offers products and services including ELISA Kits, Recombinant Proteins, and Expression Vectors. InterpretOmics operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Bengaluru, India
- Employees 56 as on 05 Apr, 2024
- Founders Amrith Prasad, Archana Prahlad
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Interpretomics India Private Limited
- Date of Incorporation 05 Dec, 2007
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$119.35 K (USD)22.72as on Mar 31, 2015
-
Net Profit
-$318.7 K (USD)-135.2as on Mar 31, 2015
-
EBITDA
-$358.23 K (USD)-140.68as on Mar 31, 2015
-
Total Equity Funding
$1.92 M (USD)
in 2 rounds
-
Latest Funding Round
$293.14 K (USD), Seed
Jan 10, 2017
-
Investors
Amarante Shipping
& 2 more
-
Employee Count
56
as on Apr 05, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InterpretOmics
InterpretOmics offers a comprehensive portfolio of products and services, including ELISA Kits, Recombinant Proteins, and Expression Vectors.
Kits for antigen detection in molecular research
Proteins for cloning and expression in biology
Vectors for rapid DNA cloning and protein purification
Funding Insights of InterpretOmics
InterpretOmics has successfully raised a total of $1.92M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $293.14 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InterpretOmics
InterpretOmics has secured backing from 3 investors, including institutional and angel investors. Prominent investors backing the company include Amarante Shipping, Somaprasad Muttael Prabhakaran and Prashant Priya.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global provider of bulk cargo shipping, trading, and vessel operations services.
|
Locked | Locked | Locked | |
|
SM
Somaprasad Muttael Prabhakaran |
-
|
Locked | Locked | Locked |
|
PP
Prashant Priya |
-
|
Locked | Locked | Locked |
Investor details for InterpretOmics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InterpretOmics
Investment portfolio details for InterpretOmics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InterpretOmics
Detailed financials for InterpretOmics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Interpretomics Comparisons
Peer comparison for InterpretOmics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InterpretOmics
InterpretOmics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
Detailed competitors of InterpretOmics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Interpretomics
Complete news archive for InterpretOmics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterpretOmics
InterpretOmics was founded in 2009 and raised its 1st funding round 4 years after it was founded.
InterpretOmics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
InterpretOmics is a funded company, having raised a total of $1.92M across 2 funding rounds to date.
As of Apr 05, 2024, the latest employee count at InterpretOmics is 56.
Annual revenue of InterpretOmics is $119.35K as on Mar 31, 2015.
InterpretOmics is an integrated genomics company providing genome-scale data analysis and interpretation product and services. The company utilizes public and proprietary databases to analyze data and interpret results. Its enterprise level genomics data analysis platform iOMICS allows researchers to analyze DNA and identify diagnostic markers that indicate disease. Omnia is a platform which provides users access to genetic data sets across a board range of disease indications. The company has also introduced GeneComplete is an NGS-based genetic test to confirm or determine the presence of disease in an individual, suspected of having a disease. It is also working on Preimplantation genetic screening (PGS) - a microarray-based powerful genetic test that may be performed on embryos during IVF treatment to screen for numerical chromosomal abnormalities and Hotspot Cancer Mutation Screening. The company also offers genetic counseling services under the umbrella of AlphaLife using genetic and biochemical tests. It has processed about 35 TB of genomics data over 40 projects for clients including Delaware State University (DSU) and AIIMS. Singapore-based shipping company, Amarante is an investor in the company.
InterpretOmics's top competitors include Guardant Health, Foundation Medicine and Helix.
InterpretOmics offers ELISA Kits, Recombinant Proteins, and Expression Vectors.
InterpretOmics has 3 investors. Key investors include Amarante Shipping, Somaprasad Muttael Prabhakaran, and Prashant Priya.
The valuation of InterpretOmics is $7.33M as of Jan 2017.